RNA-lipoplex Cancer Vaccine BNT116

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing six messenger ribonucleic acids (mRNA) each encoding for a different tumor-associated antigen (TAA) expressed in non-small cell lung cancer (NSCLC), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the RNA-lipoplex cancer vaccine BNT116, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the six tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the six selected TAAs.

**Synonyms:** - BNT 116 - BNT-116 - BNT116 - Cancer Vaccine BNT116 - FixVac Lung BNT116 - mRNA-derived NSCLC Vaccine BNT116